Only two calcineurin inhibitors exist, cyclosporine and tacrolimus, and the available formulations are once-daily slow-release tacrolimus, twice-daily immediate-release tacrolimus and twice-daily ...

Only two calcineurin inhibitors exist, cyclosporine and tacrolimus, and the available formulations are once-daily slow-release tacrolimus, twice-daily immediate-release tacrolimus, and twice-daily ...

June 12, 2009 (Boston, Massachusetts) — A 10-year retrospective analysis of kidney-transplant patients shows that tacrolimus therapy provides superior graft survival and renal function at 10 ...

Lung transplant Among lung transplant recipients, tacrolimus compared to cyclosporine may be associated with decreased incidence of bronchiolitis obliterans syndrome and number of acute rejection ...

Tacrolimus and cyclosporine A show similar efficacy in long-term survival and relapse reduction in AML post-transplant patients. No significant differences were found in leukemia-free survival ...

The researchers randomly assigned 274 patients (mean age, approximately 46 years) to tacrolimus (0.01 - 0.03 mg/kg per day intravenously [0.05 - 0.3 mg/kg orally]) or cyclosporine (1 - 3 mg/kg per ...

Please provide your email address to receive an email when new articles are posted on . Tacrolimus may be promising for patients with psoriasis or atopic dermatitis who also have cardiovascular ...

The rate of biopsy-proven acute rejection was lower in patients receiving low-dose tacrolimus (12.3%) than in those receiving standard-dose cyclosporine (25.8%), low-dose cyclosporine (24.0%), or ...

There was no good evidence suggesting that tacrolimus would perform better in this setting and before the trial, cyclosporine had been the calcineurin inhibitor of choice in Scandinavian lung ...

Only two calcineurin inhibitors exist, cyclosporine and tacrolimus, and the available formulations are once-daily slow-release tacrolimus, twice-daily immediate-release tacrolimus and twice-daily ...

Cyclosporine A (CsA ... 4,5,6,7,8,9 supporting the likelihood of CsA-induced TMA following BMT. To prevent GVHD, Tacrolimus (Tc) is given to patients undergoing BMT in a manner similar to CsA.